Market Overview

UPDATE: Morgan Stanley Reiterates On Pharmacyclics Following IMS Launch Analysis

Share:

In a report published Tuesday, Morgan Stanley analyst Matthew Harrison reiterated an Equal-Weight rating on Pharmacyclics (NASDAQ: PCYC), but removed the $100.00 price target.

In the report, Morgan Stanley noted, “We performed a detailed IMS launch analysis that suggests 2014 nums are too low, but 2015+ are too high given current trends. We see 2014 US Imbruvica sales of ~$375M (+$75M vs guide and +$42M vs cons), but 2015 sales of ~$620M (-$120M vs cons).

"Key deltas vs the Street: (1) The MCL bolus was large compared to incident pts, thus we expect little Y/Y MCL sales growth; (2) R/R CLL continues to launch, but flattening new prescriptions (NRx) point to a peak ~$120M/qtr run-rate outside of incidence/price growth; (3) We model a modest impact of off-label prescribing (16% of 2015 sales).”

Pharmacyclics closed on Friday at $87.62.

Latest Ratings for PCYC

DateFirmActionFromTo
Mar 2015DowngradesOutperformMarket Perform
Mar 2015DowngradesBuyNeutral
Mar 2015DowngradesOutperformMarket Perform

View More Analyst Ratings for PCYC
View the Latest Analyst Ratings

Posted-In: Matthew Harrison Morgan StanleyAnalyst Color Price Target Analyst Ratings

 

Related Articles (PCYC)

View Comments and Join the Discussion!

Latest Ratings

StockFirmActionPT
TOLGoldman SachsInitiates Coverage On42.0
KBHGoldman SachsInitiates Coverage On36.0
YEXTSunTrust Robinson HumphreyMaintains28.0
LHCGSunTrust Robinson HumphreyMaintains160.0
DLRSunTrust Robinson HumphreyMaintains140.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Trading Daily
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com

UPDATE: JMP Securities Reiterates On American Realty Capital Properties As Balance Sheet Transforms

Morning Market Losers